Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
KalVista Pharmaceuticals ( (KALV) ) has provided an announcement.
KalVista Pharmaceuticals appointed Jebediah T. Ledell as Chief Operating Officer effective December 16, 2024, leveraging his extensive experience in the biotechnology industry to support the company’s evolution into a commercial entity. The appointment is strategically significant as KalVista prepares for the global launch of its transformative therapy, sebetralstat, enhancing its efforts to improve treatment for hereditary angioedema.
More about KalVista Pharmaceuticals
KalVista Pharmaceuticals, Inc. is a global pharmaceutical company focused on developing and delivering oral medicines for rare diseases with significant unmet needs. Their investigational drug, sebetralstat, aims to provide on-demand treatment for hereditary angioedema and is currently under FDA review.
YTD Price Performance: -29.06%
Average Trading Volume: 406,504
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $429.4M
For an in-depth examination of KALV stock, go to TipRanks’ Stock Analysis page.
